Abstract:The immune environment in tumors is the key factor affecting the survival and immunotherapeutic response of patients. This research aimed to explore the underlying association between focal adhesion tyrosine kinase (FAK/PTK2) and cancer immunotherapy in 33 human cancers. Gene expression data and clinical features of 33 cancers were retrieved from the Cancer Genome Atlas Database. The immunotherapy cohorts included GSE67501, GSE78220, and IMVIGOR210, which were derived from the comprehensive gene expression database or from previous studies. Clinical parameters including patient age, gender, survival rate, and tumor stage were analyzed to evaluate the prognostic value of FAK/PTK2. FAK/PTK2 activity was detected by single-sample gene set enrichment analysis and used to compare the difference between FAK/PTK2 transcriptome and protein expression levels. To better understand the role of FAK/PTK2 in cancer immunotherapy, we analyzed its correlations with tumor microenvironment and with immune processes/elements (e.g., immune cell infiltration, immunosuppressants, and stimulants) and major histocompatible complexes. Potential pathways associated with FAK/PTK2 signaling in cancers were also explored. Correlations between FAK/PTK2 and 2 immunotherapeutic biomarkers (tumor mutation load and microsatellite instability) were studied. Finally, the 3 independent immunotherapy cohorts were used to study the relationship between FAK/PTK2 and immunotherapeutic response. Although FAK/PTK2 is not closely associated with age (13/33), gender (5/33), or tumor stage (5/33) in any of the studied human cancers, it has potential prognostic value for predicting patient survival. Consistency between FAK/PTK2 activity and expression exists in some cancers (3/33). Generally, FAK/PTK2 is robustly correlated with immune cell infiltration, immune modulators, and immunotherapeutic markers. Moreover, high FAK/PTK2 expression is significantly related to immune-relevant pathways. However, FAK/PTK2 is not significantly correlated with the immunotherapeutic response. Research on the immunotherapeutic value of FAK/PTK2 in 33 human cancers provides evidence regarding the function of FAK/PTK2 and its role in clinical treatment. However, given the use of a bioinformatics approach, our results are preliminary and require further validation.

Advances in the treatment of tumors with focal adhesion kinase inhibitors

Focal adhesion kinase: from biological functions to therapeutic strategies

Research and Development of Focal-Adhesion Kinase(FAK) and the Inhibitors

Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment

Lateral root bridging as a strategy to enhance L‐DOPA production in Stizolobium hassjoo hairy root cultures by using a mesh hindrance mist trickling bioreactor

Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy

Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study

Focal adhesion kinase-mediated interaction between tumor and immune cells in the tumor microenvironment: implications for cancer-associated therapies and tumor progression

Development of Novel Focal Adhesion Kinase (FAK) Inhibitors for Targeting Cancer: Structural Insights and Therapeutic Potential

FAK expression regulation and therapeutic potential

Signal transduction by focal adhesion kinase in cancer

Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders

Focal Adhesion Kinase Expression: A Potential Tumor Therapy Target

Research Progress in the Mechanism of Molecular Targeted Anti-tumor Drugs

Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics

Targeting FAK in anticancer combination therapies

Focal adhesion kinase as a new player in the biology of onco-hematological diseases: the starting evidence

[Analysis of admission to a hospital emergency service by means of a P-10 form].

Comprehensive pan-cancer analysis of 33 human cancers reveals immunotherapeutic value of focal adhesion tyrosine kinase

Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma

FAK inhibitors in cancer, a patent review - an update on progress.